Loy­ola is work­ing on a new and im­proved CAR-T prod­uct, look­ing to over­come high-fre­quen­cy side ef­fects

Loy­ola Uni­ver­si­ty Chica­go thinks it can do a bet­ter job mak­ing CAR-T ther­a­pies for pa­tients. And now it has the mon­ey to launch a pi­lot pro­gram to do just that.

These cell ther­a­pies re­ly on cells ex­tract­ed from pa­tients, reengi­neered in­to at­tack ve­hi­cles point­ed at can­cer cells and then re-in­fused in­to pa­tients as ther­a­py. Up un­til now, Loy­ola has been us­ing the CAR-T drugs on the mar­ket from No­var­tis and Gilead/Kite. But once it starts up its own man­u­fac­tur­ing op­er­a­tion, it plans to make it avail­able in Chica­go and “be­yond.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER